Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT05914779

Impact of Early Antibiotics on Non-Traumatic Out of Hospital Cardiac Arrest (OHCA)

Led by Hamad Medical Corporation · Updated on 2025-04-03

1000

Participants Needed

1

Research Sites

148 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Specific Aim : The specific aim is to conduct a randomized prospective clinical trial to determine whether no antibiotics in OHCA patients in the ED with very low likelihood of infection is non-inferior to early antibiotic treatment. Hypothesis a: 28-day all-cause mortality will be non-inferior in OHCA patients with very low likelihood of infection who do not receive antibiotic therapy compared with those who receive early antibiotic therapy Hypothesis b: There will be no difference in subsequent incidence of proven infections in the no antibiotics vs, early antibiotics groups Hypothesis c: There will be no difference in the length of ICU stay and overall hospital stay in the early antibiotics vs. no antibiotics groups

CONDITIONS

Official Title

Impact of Early Antibiotics on Non-Traumatic Out of Hospital Cardiac Arrest (OHCA)

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults aged >18 years presenting to the emergency department after out-of-hospital cardiac arrest
  • Patients with a low likelihood of infection based on specific definitions
  • Ability to provide informed consent or have consent provided by a legal surrogate or independent physician if incapacitated
Not Eligible

You will not qualify if you...

  • Patients with clear evidence of infection as defined by study criteria
  • Patients who have received antibiotics within the past week before admission
  • Patients with malignancy unless cured or in complete remission
  • Females who are pregnant
  • Known immunocompromised individuals, including those with HIV/AIDS, transplant recipients on immunosuppressants, or on long-term steroid therapy (>3 weeks of prednisone >5mg/day equivalent)
  • Patients on biologic immunologic disease modifying agents
  • Patients considered brain-dead or in a vegetative state
  • Patients transferred from another hospital, long-term care facility, or institution
  • Patients with neutropenia (total white blood cell count <1,500/mm3 or absolute neutrophil count <1,000/mm3)

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Hamad Medical Corporation

Doha, Baladiyat ad Dawhah, Qatar

Actively Recruiting

Loading map...

Research Team

A

Adeel A Butt, MBBS, MS

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

PREVENTION

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here